

Special Issue

Novel Adjuvants and Delivery Technologies for Vaccine Development

Message from the Guest Editors

The development of effective vaccines is crucial in combating infectious and non-infectious diseases and enhancing public health. Novel adjuvants and delivery technologies are essential for optimizing vaccine efficacy, as they can significantly improve immune responses and broaden the protective effects of vaccines.

We welcome submissions that encompass a range of topics, including but not limited to the following:

- Innovative Adjuvant Development: Exploration of new adjuvants that enhance immune responses.
- Targeted Delivery Systems: Research on systems that improve the specificity of antigen delivery.
- Nanotechnology in Vaccines: Studies on the application of nanomaterials for vaccine formulation.
- Clinical Efficacy Studies: Reports on clinical trials evaluating novel adjuvants and delivery methods.
- Mechanisms of Action: Investigations into how adjuvants and delivery technologies influence immune pathways.
- Combination Vaccines: Research on using adjuvants and delivery systems in multi-antigen formulations.

We look forward to receiving your contributions.

Guest Editors

Dr. Mohammad N. Uddin

College of Pharmacy, Mercer University, Atlanta, GA 30341, USA

Dr. Bernadette D'Souza

Department of Pharmaceutical, Social and Administrative Sciences, McWhorter School of Pharmacy, Samford University, Birmingham, AL 35229, USA

Deadline for manuscript submissions

31 May 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/240992

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).